0 Items
Select Page

Clostridium

Clostridium is a genus of gram-positive bacteria, which constitutes several significant human pathogens, including the causative agent of tetanus, Clostridium tetani and Clostridium difficile – a significant cause of diarrhoea.

The Native Antigen Company offers a wide range of native Clostridium difficile toxins, toxoids and related antibodies, including the C. tetani toxin, for IVD assay development and vaccine R&D.

Clostridium Background

Clostridium difficile is a gram-positive, spore-forming, anaerobic bacterium, first described in the mid-1930s and later linked to cases of pseudomembranous colitis. Studies have since shown that C. difficile is predominantly associated with cases of infectious diarrhoea in patients that have been treated with antibiotics (antibiotic-associated diarrhoea, or AAD), or whose commensal gastrointestinal flora has been disrupted. C. difficile infection can cause severe disease and death in a significant number of cases and is recognised as a leading cause of severe gastrointestinal disease and AAD in hospitalised patients (Voth, DE). The severity of the disease in each case is determined by the virulence of the C. difficile strain, the condition of the patient’s flora and the individual’s immune response to intestinal damage.

C. difficile spores are found in soil, human and animal faeces, and some processed meats, and can be transmitted from one individual to another through contact with contaminated surfaces. Toxins A and B have been identified as major C. difficilevirulence factors, which are encoded by the tcdA and tcdB genes, respectively. Both toxin A and toxin B have proinflammatory and cytotoxic activity, which causes disruption to the intestinal epithelium leading to extensive damage and cell death in the large intestine (Carter, GP).

In recent years the emergence of a hypervirulent strain of C. difficile, BI/NAP1/027 has caused an epidemic in the developed world and has raised significant concern within the global health care community. In addition to increased rates of mortality, BI/BAP1/07 has been reported in individuals previously considered to be low-risk, including outbreaks in peripartum women and health-care workers (Ghose, C). Treatment for cases of C. difficile uses antibiotic-based therapy but can be problematic due to antibiotic resistance. There is no effective licensed vaccine for the prophylactic treatment of C. difficile but significant advances are being made in this area.

Clostridium difficile Antigens

Our highly purified Clostridium difficile toxin preparations come in a variety of ribotypes and are suitable for numerous assays including cytotoxicity. Assays are available in a range of pack sizes and all come lyophilised for ease of storage and use. Our toxoids are prepared from formaldehyde treatment of toxins and are suitable for use as immunogens and in clinical diagnostics assays.

Clostridium difficile and Clostridium tetani Antibodies

Our Clostridium-specific antibodies recognise toxins and enzymes from the Clostridium genus of gram-positive bacteria. Clostridium antibodies supplied by The Native Antigen Company are suitable for use in immunoassay research and development.

These include antibodies specific for C. difficile toxins A and B, C. difficile GDH antigen (enzyme), and antibodies specific to C. tetani toxin.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for the 2019 Novel Coronavirus (SARS-CoV-2, Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Why We Need New Diagnostics for the Zika Virus

This article has been published in Volume 2, Issue 3 of the IBI journal.While Zika is no longer in the public eye, it hasn’t vanished. Recent outbreaks across Asia and Africa are reminders that Zika is alive and well, and with no effective countermeasures...

Clostridium difficile Toxins: The Nuts and Bolts

In this blog, we describe the mechanisms of action of the Clostridium difficile A and B toxins, and discuss their use in research and medicine. The Native Antigen Company provides biologically active C. diff toxins, as well as inactivated toxoids for a range of...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 14 =

Live Customer Feedback

Join our mailing list

* indicates required